Brahmer, Alexandra
Geiß, Carsten
Lygeraki, Andriani
Neuberger, Elmo
Tzaridis, Theophilos
Nguyen, Tinh Thi
Luessi, Felix
Régnier-Vigouroux, Anne
Hartmann, Gunther
Simon, Perikles
Endres, Kristina
Bittner, Stefan
Reiners, Katrin S.
Krämer-Albers, Eva-Maria
Funding for this research was provided by:
Mainz Research Center for Mental Health
SHARP initiative
Deutsche Forschungsgemeinschaft (CRC-TR-128, KR 3668/1-2)
Hermann und Lilly Schilling-Stiftung für Medizinische Forschung
Johannes Gutenberg-Universität Mainz
Article History
Received: 17 July 2023
Accepted: 6 September 2023
First Online: 6 October 2023
Declarations
:
: The experimental procedures were approved by the Human Ethics Committee Rhineland-Palatinate (for MS patients and HC: protocol number 837.019.10) or by the local ethics committee of the University of Bonn (Protocol number for glioblastoma patients Bonn: 182/08; healthy volunteers: 007/17), respectively. The Alzheimer patients were recruited from daily clinical work after having given written consent (§ 14 AVB, University Medical Center Johannes Gutenberg-University Mainz). The experimental procedures adhere to the standards of the Declaration of Helsinki of the World Medical Association. Written informed consent to participate was obtained from all patients and healthy persons.
: Not applicable.
: Miltenyi Biotec (Bergisch Gladbach, Germany) provided AB, EMKA, and KR with the multiplexed bead-based assay used in this study but was not involved in the design of the study, collection and analysis of data nor in writing the manuscript.